FDA approval of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor,78 accelerated target-based therapy in lung cancer patients replacing cytotoxic chemotherapy for first-line therapy.79, 80 For patients with EGFR-activating mutations (exon19del or L858R), erlotinib81, 82 also performed better than conventional chemotherapies, such as cisplatin. The gene discussed is EGFR; the disease is lung carcinoma.